Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer

DSpace/Manakin Repository

Show simple item record

dc.creator Perroud, Herman A
dc.creator Rico, María José
dc.creator Alasino, Carlos María
dc.creator Pezzotto, Stella Maris
dc.creator Rozados, Viviana R.
dc.creator Scharovsky, O. Graciela
dc.date.accessioned 2018-07-26T15:41:45Z
dc.date.available 2018-07-26T15:41:45Z
dc.date.issued 2013-08-27
dc.identifier.issn 0019-509X es
dc.identifier.uri http://hdl.handle.net/2133/11554
dc.description Background: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of response have been found yet that allow patient selection for treatment. AIM: To investigate the potential role as biomarkers of pro- and antiangiogenic parameters and evaluate their response in ABCP receiving metronomic Cy 50 mg p.o./day + Cel 400 mg p.o./day. Materials and Methods: Serum levels of vascular endothelial growth factor-C (VEGF-C), soluble VEGF receptors 2 and 3 (sVEGFR-2, sVEGFR-3), were measured at different time points in 13/15 patients included in a phase II trial of MCT with Cy+Cel. Results: Serum levels of sVEGFR-2 and sVEGFR-3 increased significantly during treatment (P = 0.0392; P = 0.0066, respectively). VEGF-C showed no significant modifications. Previous determinations of VEGF and TSP-1 in the same patients were utilized. VEGF/sVEGFR-2, VEGF/TSP-1, and VEGF-C/sVEGFR-3 ratios decreased significantly along the treatment (P = 0.0092; P = 0.0072; P = 0.0141, respectively). Nonsignificant variations were observed for VEGF-C/sVEGFR-2 ratio. Baseline values of VEGF/sVEGFR-2 and VEGF/TSP-1 ratios were associated with time to progression (TTP) (P = 0.0407; P = 0.0394, respectively) meanwhile baseline VEGF was marginally significant (P = 0.0716). Patients with values lower than the 50 th percentile for both ratios showed longer TTP. Conclusions: We have identified the baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios as potential biomarkers of response in ABCP treated metronomically with Cy+Cel. This finding warrants its confirmation in a higher number of patients. es
dc.format application/pdf
dc.format.extent 115-121 es
dc.language.iso eng es
dc.publisher Indian Cancer Society and Indian Society of Oncology es
dc.rights openAccess es
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/4.0/ *
dc.subject Biomarkers es
dc.subject Celecoxib  es
dc.subject Cyclophosphamide es
dc.subject metronomic chemotherapy es
dc.title Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer es
dc.type article
dc.type artículo
dc.type publishedVersion
dc.rights.holder © 2007 - 2018 Indian Journal of Cancer es
dc.relation.publisherversion http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2013;volume=50;issue=2;spage=115;epage=121;aulast=Perroud es
dc.relation.publisherversion 10.4103/0019-509X.117031 es
dc.rights.text https://creativecommons.org/licenses/by-nc-sa/4.0/ es
dc.citation.title Indian Journal of Cancer es
dc.citation.volume 50 es
dc.description.fil Fil: Perroud, Herman A. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina es
dc.description.fil Fil: Rico, María José. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina es
dc.description.fil Fil: Alasino, Carlos María. Institute of Oncology of Rosario; Rosario; Argentina. es
dc.description.fil Fil: Pezzotto, Stella Maris. Research Council of the National University of Rosario (CIUNR); Rosario; Argentina. es
dc.description.fil Fil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina. es
dc.description.fil Fil: Scharovsky, Graciela Olga. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina. es
dc.type.collection articulo
dc.type.version publishedVersion es


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

openAccess Except where otherwise noted, this item's license is described as openAccess

My Account


Search DSpace


Browse

Statistics